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Abstract
Objectives To determine the effect of human papillomavirus (HPV)
quadrivalent vaccine on the risk of developing subsequent disease after
an excisional procedure for cervical intraepithelial neoplasia or diagnosis
of genital warts, vulvar intraepithelial neoplasia, or vaginal intraepithelial
neoplasia.
Design Retrospective analysis of data from two international, double
blind, placebo controlled, randomised efficacy trials of quadrivalent HPV
vaccine (protocol 013 (FUTURE I) and protocol 015 (FUTURE II)).
Setting Primary care centres and university or hospital associated health
centres in 24 countries and territories around the world.
Participants Among 17 622 women aged 15–26 years who underwent
1:1 randomisation to vaccine or placebo, 2054 received cervical surgery
or were diagnosed with genital warts, vulvar intraepithelial neoplasia, or
vaginal intraepithelial neoplasia.
Intervention Three doses of quadrivalent HPV vaccine or placebo at
day 1, month 2, and month 6.
Main outcome measures Incidence of HPV related disease from 60
days after treatment or diagnosis, expressed as the number of women
with an end point per 100 person years at risk.
Results A total of 587 vaccine and 763 placebo recipients underwent
cervical surgery. The incidence of any subsequent HPV related disease
was 6.6 and 12.2 in vaccine and placebo recipients respectively (46.2%
reduction (95% confidence interval 22.5% to 63.2%) with vaccination).
Vaccination was associated with a significant reduction in risk of any
subsequent high grade disease of the cervix by 64.9% (20.1% to 86.3%).
A total of 229 vaccine recipients and 475 placebo recipients were
diagnosed with genital warts, vulvar intraepithelial neoplasia, or vaginal
intraepithelial neoplasia, and the incidence of any subsequent HPV
related disease was 20.1 and 31.0 in vaccine and placebo recipients
respectively (35.2% reduction (13.8% to 51.8%)).
ConclusionsPrevious vaccination with quadrivalent HPV vaccine among
women who had surgical treatment for HPV related disease significantly
reduced the incidence of subsequent HPV related disease, including
high grade disease.
Trial registrations NCT00092521 and NCT00092534
Correspondence to: E A Joura elmar.joura@meduniwien.ac.at
Extra material supplied by the author: Supplementary tables 1 and 2 showing effects of using 60 day or 90 day interval between initial surgery or
disease diagnosis and subsequent disease diagnoses on vaccine efficacy estimates (see
http://www.bmj.com/content/344/bmj.e1401?tab=related#webextra)
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Introduction
The currently available human papillomavirus (HPV) vaccines
that are based on recombinant virus-like particles are designed
to prevent HPV associated disease. Both the quadrivalent
vaccine (against HPV types 6, 11, 16, and 18) and the bivalent
vaccine (against types 16 and 18) are highly effective in
preventing cervical intraepithelial neoplasia grade II-III or
adenocarcinoma in situ in women who are not infected with the
relevant HPV type before vaccination.1-5 The quadrivalent
vaccine has also been shown to prevent HPV related vulvar
intraepithelial neoplasia grade II-III, vaginal intraepithelial
neoplasia grade II-III, and genital warts in women and to prevent
genital warts and high grade anal disease in men.1 6-9
Current data show that HPV vaccination does not reduce
progression to cervical precancers in women with ongoing
infections at the time of vaccination.5 10 11 However, no studies
to date have looked at the impact of HPV vaccination in
preventing subsequent disease after treatment for such
precancers. In two recent phase III clinical trials of the
quadrivalent HPV vaccine, more than 17 000 women were
followed for approximately four years. Participants who
underwent treatment for cervical, vulvar, or vaginal disease
continued to be followed until the end of the study.We therefore
had a unique opportunity to evaluate the post-treatment effect
of vaccination in these women. In this retrospective analysis
we identified women who had an excisional procedure for
cervical disease or who were diagnosed with genital warts,
vulvar intraepithelial neoplasia, or vaginal intraepithelial
neoplasia after randomisation to vaccine or placebo and followed
these women for additional disease outcomes. The objective of
this study was to determine if the vaccine decreased the risk of
developing subsequent disease after the first definitive treatment.
Methods
Objectives
The primary objective of this retrospective analysis was to
determine whether administration of quadrivalent HPV vaccine,
compared with placebo, reduced the incidence of subsequent
HPV related disease amongwomenwho had undergone surgery
for cervical disease or who were diagnosed with vulvar or
vaginal disease (genital warts, vulvar intraepithelial neoplasia,
or vaginal intraepithelial neoplasia) after enrolment into the
FUTURE I or FUTURE II clinical trials (fig 1⇓). Subsequent
HPV related disease is defined as any disease that was detected
at least 60 days after treatment or diagnosis. We measured the
vaccine’s impact on end points that were associated with HPV
types 6, 11, 16, and 18 specifically and on end points irrespective
of causal HPV type.
Study population
Between December 2001 and May 2003, 17 622 women aged
15–26 years were enrolled in one of two randomised, double
blind, placebo controlled trials (FUTURE I and FUTURE II).1 2
The studies were conducted in accordance with principles of
Good Clinical Practice and were approved by the appropriate
institutional review boards and regulatory agencies.
The study designs and the results of the primary hypotheses
have been described elsewhere.1 2 Women were eligible to
participate if they were not pregnant, did not report previous
abnormal results on a cervical smear test, and had had a lifetime
number of no more than four sex partners. Neither study
included HPV testing (DNA or serology testing) or clinical
examination before randomisation; thus, the trials allowed the
enrolment of women with ongoing HPV infection or disease.
Intervention
In both trials, participants were randomly assigned (1:1) to
receive intramuscular injections of quadrivalent HPV vaccine
(Gardasil or Silgard,Merck,Whitehouse Station, NJ) or visually
indistinguishable placebo at day 1, month 2, and month 6.
Comprehensive anogenital examinations and ThinPrep cervical
cytology (Cytyc, Boxborough, MA, USA) were performed
during scheduled visits, which occurred every 6–12 months
after the vaccination phase.1 2 Cytology specimens were
classified according to the Bethesda System 2001.12 Women
reported any abnormality or suspected disease in between the
scheduled study visits. All participants were required to use
birth control during the vaccination phase (day 1 through to
month 7), and all participants were evaluated for pregnancy
before the administration of each dose of vaccine or placebo
with a human chorionic gonadotropin assay sensitive to 25
international units.13 Counselling about safe sex and
contraceptive use was part of the study protocol.
Protocol specified guidelines were used to triage women with
smear test abnormalities to colposcopy.1 2 Colposcopists were
trained to locate and biopsy all discrete abnormal areas on the
cervix and lower genital tract. Loop electrosurgical excision
was the preferred method for definitive therapy for cervical
intraepithelial neoplasia grade II-III, adenocarcinoma in situ,
and persistent cervical intraepithelial neoplasia grade I.
However, other methods included cervix conisation,
cryotherapy, and electrocauterisation. The frequencies of each
technique recorded were loop electrosurgical excision (84.7%),
cervical conisation (12.5%), cryotherapy (0.7%), and other
(2.1%). As loop electrosurgical excision and cervix conisation
accounted for 97.2% of the procedures performed, with no
difference between the treatment groups (97.1% with placebo,
97.4% with vaccine) we use the term “cervical surgery” to
describe anymethod used to treat cervical disease. Management
of vulvar or vaginal disease followed the investigational site’s
standards and practice and included surgical or topical therapy.
Population for retrospective subanalysis
In this retrospective, intention to treat analysis, we identified
all women who underwent definitive cervical therapy or who
were diagnosed with vulvar or vaginal disease in the pooled
FUTURE I and II studies after being randomised to and
receiving at least one dose of HPV vaccine or placebo. The
incidence rates for subsequent disease were calculated with case
counting starting 60 days after cervical surgery or diagnosis of
vulvar or vaginal disease.
Rationale for 60 day window to define
subsequent disease
As stated previously, women were referred for colposcopy and
cervical surgery in accordance with a triage algorithm.1 2 In
FUTURE I, the pre-specified primary end points included all
HPV related anogenital disease, thus the study included stringent
criteria for disease determination and follow-up, including more
frequent examinations and screening and more aggressive
colposcopy triage for suspected disease. In FUTURE II, the
primary end point was cervical intraepithelial neoplasia grade
II-III and adenocarcinoma in situ. Treatment of vulvar or vaginal
disease in FUTURE II was based on local standards of care,
and the investigators were not required to record the date or
method of treatment. We therefore examined the average time
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from diagnosis to treatment of genital warts, vulvar
intraepithelial neoplasia, and vaginal intraepithelial neoplasia
within the FUTURE I study. That information was used to
determine an appropriate time frame after which most women
would have been treated, so that follow-up after that window
would probably capture new, rather than residual, disease. In
FUTURE I, the mean number of days between diagnoses and
treatment of genital warts, vulvar intraepithelial neoplasia, and
vaginal intraepithelial neoplasia was 28 days (interquartile range
0–42 days). As the trials were less than four years of total
duration (mean of 3.6 years), and since 82% had treatment
within 60 days of the pathology panel diagnosis, we choose this
as the cut off to ensure there would be enough follow-up time
to detect subsequent disease after treatment. We assumed a
similar time window between treatment and diagnosis in
FUTURE II, and used the same window (60 days after
diagnosis) for both studies. For consistency, the same time
window was applied for counting subsequent disease after
cervical surgery. A sensitivity analysis was also performed using
a 90 day time window, as 91% of subjects had treatment within
90 days.
Efficacy end points and statistics
All specimens from biopsies and excisional procedures were
tested for 14 HPV types (6, 11, 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, and 59) using an assay based on the polymerase
chain reaction.14-16 All tissue specimens underwent
histopathological review by a pathology panel, who were
masked to the women’s vaccination group and HPV status. A
woman was considered to have developed an end point related
to vaccine HPV types (HPV 6, 11, 16, or 18) or an end point
related to 10 non-vaccine types (HPV 31, 33, 35, 39, 45, 51,
52, 56, 58, or 59) if the respective HPV DNA were detected in
the same lesion that was diagnosed by the pathology panel as
cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia,
vaginal intraepithelial neoplasia, or genital warts. For analyses
of all disease, irrespective of causal HPV type, a woman was
considered to have developed an end point if she had a lesion
diagnosed by the pathology panel without consideration of HPV
status.
In the analyses (presented in tables 2–4⇓⇓⇓) a woman is counted
only once for each end point (that is, once in each row), but a
woman may have developed more than one end point during
the trial (that is, a women may appear in more than one row).
For example, a woman who is diagnosed with a cervical
intraepithelial grade 3 lesion that is positive to HPV types 16,
31, and 45 would be counted once for (1) any disease; (2) any
cervical disease; (3) any cervical intraepithelial grade II or
worse; (4) any cervical intraepithelial grade III or worse; (5)
any disease related to vaccine HPV types; (6) cervical
intraepithelial grade I or worse related to vaccine HPV types;
(7) cervical intraepithelial grade II or worse related to vaccine
HPV types; and (8) cervical intraepithelial grade III or worse
related to vaccine HPV types.
Women contributed to person years at risk from 60 days after
the initial surgery or diagnosis until the day of ascertainment
of the subsequent disease end point, or, for those without a
subsequent disease end point, until the day of their last follow-up
visit. Incidence, or rate of subsequent disease, is expressed as
the number of women with an end point per 100 person years
at risk. A point estimate of vaccine efficacy (that is, percentage
reduction of the relative end point) and the 95% confidence
interval were calculated on the basis of the observed case split
between vaccine and placebo recipients, adjusted for the accrued
person time in each group. The criterion for statistical
significance (P<0.05) was equivalent to requiring that the lower
bound of the confidence interval for vaccine efficacy exclude
0%. An exact conditional procedure was used to evaluate
vaccine efficacy under the assumption that the numbers of cases
in the vaccine and placebo groups were independent Poisson
random variables.17
Kaplan-Meier estimates (and 95% confidence intervals) of
cumulative incidence rates for subsequent disease were plotted
with case counting starting 60 days after cervical surgery or
vulvar or vaginal disease diagnosis.18 The plots were not part
of a formal survival analysis; rather they give a visual
demonstration of the divergence of the incidence rates between
the two vaccination arms over time. The 95% confidence interval
for the Kaplan-Meier incidence at intervals of six months are
not directly comparable with vaccine efficacy estimates. Vaccine
efficacy was calculated from the exact conditional procedure
and is included in the Kaplan-Meier plots as a reference.
Results
Analysis population
The FUTURE I and II trials collectively enrolled and
randomised 17 622 women. The populations analysed to
determine the impact of quadrivalent HPV vaccine on
subsequent disease is shown in fig 2⇓. Of the 1350 women
included in the analysis, only five (three placebo recipients, two
vaccine recipients) received fewer than all three doses, with one
woman in the placebo group having only one dose, and the
others receiving two doses each. These women stopped the
vaccination phase because pregnancy (two women), lactation
(one), medical history (one), and unknown reason (one), but
continued the follow-up phase of the study.
As expected, more placebo recipients underwent cervical surgery
for disease due to any HPV type (n=763) than vaccine recipients
(n=587). Among women who underwent cervical surgery,
vaccine recipients had numerically higher baseline (at day 1 of
the study) prevalence of squamous intraepithelial lesions
(36.5%) compared with placebo recipients (30.0%) and higher
prevalence of HPV DNA (70.1%) than placebo (62.0%) (table
1⇓). Amongwomenwho had a diagnosis of genital warts, vulvar
intraepithelial neoplasia, or vaginal intraepithelial neoplasia,
vaccine recipients also had a higher baseline prevalence than
placebo recipients of squamous intraepithelial lesions (27.0%
v 14.2%) and HPV DNA (65.9% v 44.0%) and a lower
proportion of current or former smokers (36.7% v 43.4%).
Incidence of subsequent disease in placebo
group
Placebo recipients who were treated for HPV related disease in
these clinical trials were at increased risk for developing
subsequent HPV related disease (fig 3⇓). Within an average of
only 1.3 years after cervical surgery (maximum follow-up of
3.7 years), the incidence of any subsequent disease among
placebo recipients was 12.2 per 100 person years at risk, and
5.2% (31/593) developed subsequent high grade cervical, vulvar,
or vaginal disease (incidence of 3.7). Compared with those who
underwent cervical surgery, those who were diagnosed with
genital warts, vulvar intraepithelial neoplasia, or vaginal
intraepithelial neoplasia had nearly three times the risk for
developing any subsequent HPV related disease (incidence of
31.0). Within an average of only 1.2 years after the initial
diagnosis of vulvar or vaginal disease (maximum follow-up of
4.0 years), 13.0% (55/422) developed high grade cervical,
vulvar, or vaginal disease (incidence of 8.4). For both analysis
populations, the incidence of subsequent low grade disease
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(genital warts; vulvar or vaginal or intraepithelial neoplasia
grade I; or cervical intraepithelial neoplasia grade I) was also
high (10.1 to 26.1).
Impact of prior vaccination on disease after
cervical surgery
Vaccination was associated with a significantly reduced risk of
any subsequent HPV related disease after cervical surgery,
irrespective of causal HPV type, by 46.2% (95% confidence
interval 22.5% to 63.2%) (table 2⇓). Vaccination was associated
with a significantly reduced risk of any subsequent cervical
disease (by 48.3% (95% confidence interval 19.1% to 67.6%)
for cervical intraepithelial neoplasia grade I or worse) and any
subsequent high grade cervical disease (64.9% (20.1% to 86.3%)
for cervical intraepithelial neoplasia grade II or worse). A
significant reduction in the incidence of genital warts was
observed (63.0% (10.3% to 86.6%)). Vaccination was also
associated with significantly reduced risk of any subsequent
disease related to vaccine HPV types (79.1% (49.4% to 92.8%)).
The impact on vulvar or vaginal disease was primarily driven
by a reduction in the incidence of genital warts. Vaccine
recipients saw an 89.0% reduction (54.9% to 98.7%) in genital
warts related to vaccine HPV types after cervical surgery.
Vaccine efficacy estimates were similar in the sensitivity
analysis which used a 90 day interval between the first and
subsequent disease diagnoses (see supplementary table 1 on
bmj.com).
As shown in table 2⇓, two vaccine and nine placebo recipients
developed cervical disease related to vaccine HPV types after
their first cervical surgery. Of the two women in the vaccine
arm, one developed cervical intraepithelial neoplasia grade I
and II lesions related to HPV type 16 after surgery. This woman
was DNA positive to HPV types 16, 31, 56, and 58 at study
entry and had HPV types 16 and 58 detected in her original
surgical specimen. The second woman developed a cervical
intraepithelial neoplasia grade I lesion related to HPV 18. She
was DNA positive to HPV 18 at day 1 (and was negative to the
other 11 tested high risk HPV types) but underwent
electrocauterisation, so no surgical specimen existed. Of the
nine women in the placebo armwho developed cervical disease
related to vaccine HPV types, six (67%) did not have the same
vaccine HPV type detected in their original surgical specimen.
Table 3⇓ shows the vaccine efficacy for cervical intraepithelial
neoplasia grade I or worse due to 10 high risk, non-vaccine HPV
types after surgery for cervical disease. Vaccination was
associated with reduction of cervical intraepithelial neoplasia
grade I or worse associated with HPV31, 33, 45, 52, 58 (the
five most common HPV types found in cervical cancer after
HPV16 and HPV18) by 56.6% (3.4% to 82.3%). For individual
HPV types, a significant reduction was observed for HPV31
(88.4%, [18.6% to 99.7%]). A positive percent reduction was
observed for seven of the other types analysed, though the data
did not reach statistical significance.
Fig 4⇓ shows the divergence of incidence rates over time for
any subsequent disease and any subsequent vulvar or vaginal
disease, irrespective of causal HPV type. Among both vaccine
and placebo recipients, the incidence of any subsequent HPV
related disease (fig 4A) had not reached a plateau by the end of
study, and the divergence of incidence between the vaccine
group and the placebo group increased at each six month
interval. In contrast, the incidence of subsequent vulvar or
vaginal disease after cervical surgery seemed to have reached
a plateau for both vaccine and placebo recipients by end of study
(fig 4B).
Impact of prior vaccination on disease after
diagnosis of genital warts or of vulvar or
vaginal intraepithelial neoplasia
Vaccination was associated with a reduced risk of any
subsequent HPV related disease, irrespective of causal HPV
type, by 35.2% (13.8% to 51.8%) (table 4⇓). For end points
related to vaccine HPV types, there was a 64.4% reduction
(41.6% to 79.3%) in any disease observed. Fig 4⇓ shows the
divergence of incidence rates over time for any subsequent
disease, and any subsequent cervical disease, irrespective of
causal HPV type. Among both vaccine and placebo groups, the
incidence of any subsequent disease (fig 4C) and any subsequent
cervical disease (fig 4D) had not reached a plateau by end of
study. Vaccine efficacy estimates were similar in the sensitivity
analysis which used a 90 day interval between initial surgery
or disease diagnosis and subsequent disease diagnoses
(supplementary table 2 on bmj.com).
Impact of prior vaccination on recurrent
genital warts and low grade disease
In the previous analyses, we considered the impact of
vaccination collectively among women who were diagnosed
with genital warts, vulvar intraepithelial neoplasia grade I or
worse, or vaginal intraepithelial neoplasia grade I or worse. If
we consider only those womenwhowere diagnosed with genital
warts, there were 134 vaccine and 351 placebo recipients,
respectively. The average time to the first detection of genital
warts in these women was 1.4 years in the vaccine group and
2.1 years in the placebo group. Of these women, 43.3% (58/134)
vaccine recipients and 14.8% (52/351) placebo recipients were
infected with HPV types 6 or 11 at study entry. When we
followed these women for recurrent genital warts, vaccination
was associated with less recurrence of genital warts related to
vaccine HPV types by 46.8% (10 cases in vaccine group v 33
cases in placebo group), but the reduction was not statistically
significant.
A similar analysis was performed for recurrent vulvar or vaginal
low grade disease (genital warts, vulvar intraepithelial neoplasia
grade I, or vaginal intraepithelial neoplasia grade I). There were
210 vaccine recipients and 445 placebo recipients who were
diagnosed with low grade disease. Vaccination was associated
with reduced risk of subsequent low grade disease related to
vaccine HPV types by 60.3% (21.7% to 81.5%).
Discussion
Our results of the subgroup analysis demonstrate that vaccination
with the quadrivalent HPV vaccine was associated with reduced
incidence of subsequent cervical, vulvar, and vaginal
intraepithelial neoplasia and genital warts in women who had
been diagnosed and treated for cervical and vulvar or vaginal
disease. After treatment for high grade cervical intraepithelial
neoplasia, women are at increased risk for cervical cancer in
the long term,19 and our data show they are at risk for subsequent
diagnoses of premalignant disease in the short term.Within two
years after treatment, those with prior vaccination had
significantly reduced risk of subsequent high grade cervical
disease. Our analysis also shows that for women who were
diagnosed with HPV related vulvar or vaginal disease, those
with prior vaccination had significantly reduced risk of
developing any subsequent HPV related disease as well as
disease related to the vaccine HPV types (types 6, 11, 16, and
18). These are, to our knowledge, the first results in vaccinated
womenwho have undergone treatment for HPV related diseases.
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Strengths of study
We took several steps to enhance the accuracy, reproducibility,
and generalisability of our findings. We considered all disease
end points, irrespective of causal HPV type. Histological
diagnoses were determined by a panel of expert gynaecologic
pathologists whowere unaware of women’s treatment or history
of cervical or vulvar disease. Generalisability was enhanced by
enrolling women from both developed and developing nations
and by using standard management algorithms for treatment of
cervical disease and local standards of care for treatment of
vulvar or vaginal disease.20 21
In addition to measuring the impact on precancerous lesions,
we also measured the impact on low grade disease. Although
low grade cervical and vulvar or vaginal lesions are considered
to be a morphological manifestation of an HPV infection, these
lesions contribute to the clinical and economic burden of HPV
disease. For example, the psychosocial22-24 and economic25 26
implications of genital warts are substantial and reflect, in part,
the high transmission and recurrence rates.27-29 Lesion and
infection are a local phenomenon of the transformation zone at
the cervix, which is completely removed by treatment, whereas
vulvovaginal disease is a field infection (infectious areas are
not completely removed by the treatment and, therefore, the
recurrence rate is high). In contrast to breast and cervical
cancers, there are no screening programmes for vaginal and
vulvar malignancies, and precursors of vulvar and vaginal
cancers are often not recognised.7 Cervical, vulvar, and vaginal
intraepithelial neoplasia grade I and genital warts have also been
shown to contain a variety of high risk HPV types.6 30-33 In this
study, the highest rates of subsequent disease observed was low
grade, and vaccination rapidly and significantly reduced the
onset of subsequent low grade lesions, particularly among
women who underwent cervical surgery.
Comparison with other studies
These data are in line with previous studies that suggest the
benefits of vaccination are not limited to the primary target
group of young, sexually naïve girls. In an intention to treat
analysis that measured the impact of the quadrivalent HPV
vaccine in a mixed population of HPV naïve and HPV infected
women, vaccination significantly reduced the number of
abnormal smear test results and procedures such as colposcopy,
biopsy examination, and definitive therapy irrespective of the
causal HPV type.34 Another study has shown the quadrivalent
HPV vaccine generates an anamnestic response (renewed rapid
production of an antibody on a subsequent encounter with the
same antigen) in women aged 15–26who are seropositive before
vaccination,35 36 and that the quadrivalent HPV vaccine prevents
reinfection or reactivation of disease that is related to vaccine
HPV types.37 For example, women who had cleared an HPV16
infection in the past were protected from developing subsequent
HPV16 related disease.37 A previous study has shown that
women who are infected with one or more vaccine HPV types
derive residual benefit by the quadrivalent HPV vaccine’s
prevention of infection and disease from HPV type(s) to which
the woman has not yet been exposed.38 The vaccine is also
effective in women up to the age of 45, whereby prophylactic
vaccine efficacy against disease related to vaccine HPV types
was 92.4% (49.6% to 99.8).39 40
Limitations of study
This retrospective analysis is accompanied by some limitations.
The trials were not designed or powered to evaluate the effects
of vaccination after cervical surgery or diagnosis. Women with
a prior history of HPV related disease were excluded from
enrolment, so we cannot directly measure the vaccine’s impact
in women who have undergone treatment before vaccination,
since all women in this study were vaccinated before treatment.
As a surrogate, we identified women who were treated for HPV
related disease after randomisation and followed them for
additional disease outcomes. In this relatively low risk
population (healthy women with a mean of two lifetime sexual
partners and no prior history of HPV related disease) the risk
of subsequent disease after a diagnosis of HPV related vulvar
or vaginal disease was about three times higher than after
cervical surgery. Although the reasons for this are unclear, our
data indicate that womenwhowere diagnosed with HPV related
disease were a high risk group at study entry, as nearly half of
these women (44–70%) were infected with at least one of the
14 tested HPV types, and 14–37% had abnormal cytology at
day 1.
There was an imbalance in some baseline characteristics (that
is, at day 1) as a result of our selection of patients who had
treatment for cervical or vulvovaginal disease after vaccination
that may have potentially biased these results. Among women
who had a pathology panel diagnosis of vulvar or vaginal
disease, placebo recipients had a higher proportion of current
or former smokers (43.4%) compared with vaccine recipients
(36.7%), and women who smoke are about twice as likely as
non-smokers to get cervical cancer.41 However, the most
important risk factor for cervical cancer is infection by HPV,41
and, because of our subsetting to those who later received
treatment for cervical or vulvovaginal disease, vaccine recipients
had numerically higher day 1 prevalence of HPVDNA and day
1 prevalence of squamous intraepithelial lesions compared with
placebo recipients. In spite of these potential biases, there were
still significant reductions in subsequent disease for vaccine
recipients compared with placebo recipients.
It is important to note that most of the “first” disease detected
in both vaccine and placebo recipients was a result of these
infections that were present at day 1, and not due to vaccine
failure. It is also important to note that the impact of the vaccine
in preventing subsequent disease does not indicate that
vaccination provides a therapeutic effect. Though it is possible
that some of the cervical disease detected after cervical definitive
therapy is residual, these data suggest that most of the
subsequent disease is from an infection with an HPV type that
was not the causal type of the first lesion. For example, we
found that six of the nine women in the placebo arm who
developed cervical disease related to vaccine HPV types after
surgery had a vaccine HPV type that was not detected in the
original surgical specimen, suggesting that the lesion diagnosed
after surgery was from a new infection and not from residual
disease. Four of the six women in the placebo group who
developed cervical intraepithelial neoplasia related to a vaccine
HPV type after surgery that was not in the original surgical
specimen also reported at least one new sexual partner in the
interval between the first cervical surgery and the subsequent
disease diagnosis. We have also previously shown that
vaccination of women who were negative to 14 HPV types at
enrolment reduced the incidence of cervical intraepithelial
neoplasia grade III or worse associated with 10 non-vaccine
HPV types by 32.5% (6.0% to 51.9%), and the present analyses
suggest some of the subsequent disease that is prevented is due
to protection against HPV types that are phylogenetically related
to vaccine HPV types (6, 11, 16, and 18).42 Although the exact
underlying mechanism is not fully known, these observed
reductions are felt to be clinically significant.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e1401 doi: 10.1136/bmj.e1401 (Published 27 March 2012) Page 5 of 14
RESEARCH
Conclusions
At present, in the United States and other countries, HPV testing
before HPV vaccination is not recommended.43 Data to date
indicate HPV vaccination does not reduce progression to cervical
pre-cancers in women with ongoing infection, and cervical
cancer screening and corresponding management should
continue as per local guidelines.5 10 11 Our study confirms that
vaccination does not reduce progression to disease in women
who are infected with HPV at the time of vaccination, but
women who were treated for disease in the context of these
studies were at risk for developing subsequent disease, and
vaccination offered substantial benefit. Prophylactic HPV
vaccines have been shown to remain efficacious for at least 10
years,44 and so it can be anticipated that vaccinated women will
continue to benefit from a reduction in disease risk in the long
term. However, only long term surveillance of vaccinated
populations can determine the population effectiveness of
vaccination. Several programmes to monitor both the safety and
the impact of HPV vaccines on disease outcomes are in place.45 46
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Tables
Table 1| Characteristics at study enrolment (day 1) of women aged 15–26 years who had undergone cervical surgery or had a diagnosis
of vulvar or vaginal disease* after randomisation to quadrivalent HPV vaccine or placebo. Values are numbers (percentages) unless stated
otherwise
Women who had diagnosis of vulvar or vaginal disease*Women who had cervical surgery
Placebo (n=475)Vaccine (n=229)Placebo (n=763)Vaccine (n=587)
19.3 (2.1)19.9 (1.9)19.8 (2.0)19.9 (2.0)Mean (SD) age (years)
Race or ethnicity:
14 (2.9)6 (2.6)18 (2.4)15 (2.6)Asian
33 (6.9)7 (3.1)41 (5.4)23 (3.9)Black
88 (18.5)49 (21.4)110 (14.4)76 (12.9)Hispanic American
1 (0.2)01 (0.1)0Native American
304 (64.0)136 (59.4)520 (68.2)407 (69.3)White
35 (7.4)31 (13.5)73 (9.6)66 (11.2)Other
Smoking status:
177 (37.3)64 (27.9)260 (34.1)187 (31.9)Current
29 (6.1)20 (8.7)46 (6.0)45 (7.7)Former
269 (56.6)145 (63.3)457 (59.9)355 (60.5)Never
23 (4.8)4 (1.7)20 (2.6)9 (1.5)Virgins
Non-virgins’ lifetime No of sexual partners:
123/452 (27.2)64/225 (28.4)179/743 (24.1)117/578 (20.2)1
132/452 (29.2)60/225 (26.7)201/743 (27.1)148/578 (25.6)2
97/452 (21.5)51/225 (22.7)168/743 (22.6)143/578 (24.7)3
83/452 (18.4)41/225 (18.2)174/743 (23.4)156/578 (27.0)4
17/452 (3.8)9/225 (4.0)21/743 (2.8)14/578 (2.4)≥5
2223Median
HPV infection and disease at baseline
66/464 (14.2)61/226 (27.0)225/749 (30.0)208/570 (36.5)Squamous intraepithelial lesion present on
cytology:
17/464 (3.7)16/226 (7.1)65/749 (8.7)47/570 (8.2)Atypical cells of undetermined significance
3/464 (0.6)0/226 (0.0)10/749 (1.3)13/570 (2.3)Atypical cells, cannot exclude high grade lesion
45/464 (9.7)42/226 (18.6)120/749 (16.0)112/570 (19.6)Low grade lesion
1/464 (0.2)3/226 (1.3)29/749 (3.9)36/570 (6.3)High grade lesion
0/464 (0.0)0/226 (0.0)1/749 (0.1)0/570 (0.0)Atypical glandular cells
208/473 (44.0)151/229 (65.9)471/760 (62.0)410/585 (70.1)PCR positive for ≥1 HPV type at baseline†:
112/473 (23.7)95/228 (41.7)262/759 (34.5)254/584 (43.5)Vaccine HPV type:
55/473 (11.6)60/226 (26.5)60/754 (8.0)59/582 (10.1)HPV6
5/473 (1.1)6/228 (2.6)6/757 (0.8)13/582 (2.2)HPV11
52/473 (11.0)45/228 (19.7)187/755 (24.8)183/581 (31.5)HPV16
24/473 (5.1)12/228 (5.3)57/757 (7.5)60/580 (10.3)HPV18
165/472 (35.0)107/229 (46.7)389/758 (51.3)333/584 (57.0)Non-vaccine type:
31/471 (6.6)17/228 (7.5)96/755 (12.7)78/577 (13.5)HPV31
13/472 (2.8)5/228 (2.2)44/754 (5.8)32/582 (5.5)HPV33
13/472 (2.8)7/228 (3.1)40/752 (5.3)32/582 (5.5)HPV45
41/472 (8.7)23/228 (10.1)102/755 (13.5)79/581 (13.6)HPV52
25/472 (5.3)10/228 (4.4)81/757 (10.7)62/581 (10.7)HPV58
9/472 (1.9)8/229 (3.5)29/756 (3.8)39/581 (6.7)HPV35
30/472 (6.4)21/228 (9.2)71/753 (9.4)68/580 (11.7)HPV39
44/472 (9.3)34/227 (15.0)112/752 (14.9)101/581 (17.4)HPV51
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Table 1 (continued)
Women who had diagnosis of vulvar or vaginal disease*Women who had cervical surgery
Placebo (n=475)Vaccine (n=229)Placebo (n=763)Vaccine (n=587)
39/471 (8.3)31/227 (13.7)115/753 (15.3)105/579 (18.1)HPV56
32/471 (6.8)16/228 (7.0)66/754 (8.8)56/580 (9.7)HPV59
HPV=human papillomavirus. PCR=polymerase chain reaction.
*Comprises genital warts, vulvar intraepithelial neoplasia, or vaginal intraepithelial neoplasia.
†Positive for ≥1 of the listed HPV types at day 1 on at least 1 required swab or (if obtained) biopsy sample.
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Table 2| Impact of quadrivalent HPV vaccine on incidence of subsequent HPV related disease* among women who had undergone cervical
surgery
% reduction (95% CI) in
rate with vaccine
Placebo (n=763)Vaccine (n=587)
End point Rate‡
No of women with a
lesion†Rate‡
No of women with a
lesion†
HPV related disease irrespective of causal HPV type
46.2 (22.5 to 63.2)12.294/5936.645/475Any disease:
48.3 (19.1 to 67.6)8.265/5924.330/474Cervical intraepithelial neoplasia
grade I or worse
63.0 (10.3 to 86.6)2.622/5891.07/474Genital warts
26.5 (−59.5 to 67.5)2.319/5891.712/474Vulvar or vaginal intraepithelial
neoplasia grade I or worse
64.9 (20.1 to 86.3)3.126/5921.18/474Cervical intraepithelial neoplasia
grade II or worse
73.5 (3.4 to 95.2)1.513/5920.43/474Cervical intraepithelial neoplasia
grade III or worse
30.1 (−259.1 to 89.2)0.65/5890.43/474Vulvar or vaginal intraepithelial
neoplasia grade II or worse
Disease related to vaccine HPV types (6, 11, 16, or 18)
79.1 (49.4 to 92.8)3.933/5930.86/475Any disease:
74.2 (−24.8 to 97.3)1.19/5920.32/474Cervical intraepithelial neoplasia
grade I or worse
89.0 (54.9 to 98.7)2.521/5890.32/474Genital warts
61.3 (−116.7 to 96.2)0.76/5890.32/474Vulvar or vaginal intraepithelial
neoplasia grade I or worse
61.3 (−382.4 to 99.3)0.43/5920.11/474Cervical intraepithelial neoplasia
grade II or worse
NA0.00/5920.00/474Cervical intraepithelial neoplasia
grade III or worse
61.2 (−383.1 to 99.3)0.43/5890.11/474Vulvar or vaginal intraepithelial
neoplasia grade II or worse
HPV=human papillomavirus.
*Any HPV related disease detected ≥60 days after surgery.
†Number of women with at least one follow-up visit for the respective end point after surgery. A woman is counted only once for each end point (that is, once in
each row) but may have developed more than one end point (and so may appear in more than one row).
‡Cases per 100 person years at risk.
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Table 3| Impact of quadrivalent HPV vaccine on incidence of subsequent cervical intraepithelial neoplasia grade I or worse* associated
with 10 tested non-vaccine HPV types among women who had undergone cervical surgery
% reduction (95% CI) in rate
with vaccine
Placebo (n=763)Vaccine (n=587)
HPV type Rate‡
No of women with a
lesion†Rate‡
No of women with a
lesion†
42.5 (−5.9 to 69.8)4.134/5922.417/474Any tested non-vaccine
type:
56.6 (3.4 to 82.3)2.924/5921.29/474HPV types 31, 33, 45,
52, or 58
88.4 (18.6 to 99.7)1.210/5920.11/474HPV31
22.1 (−579.7 to 93.5)0.33/5920.32/474HPV33
−76.3 (−2010.8 to 79.8)0.22/5920.43/474HPV35
−16.8 (−772.3 to 84.4)0.43/5920.43/474HPV39
100.0 (−76.2 to 100.0)0.54/5920.00/474HPV45
83.4 (−29.1 to 99.6)0.87/5920.11/474HPV51
41.7 (−87.1 to 84.4)1.210/5920.75/474HPV52
68.2 (−20.2 to 94.3)1.311/5920.43/474HPV56
76.6 (−108.9 to 99.5)0.65/5920.11/474HPV58
61.1 (−384.9 to 99.3)0.33/5920.11/474HPV59
HPV=human papillomavirus.
*Cervical intraepithelial neoplasia detected ≥60 days after surgery.
†Number of women with at least one follow-up visit for the respective end point after surgery. A woman is counted only once for each end point (that is, once in
each row) but may have developed more than one end point (and so may appear in more than one row).
‡Cases per 100 person years at risk.
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Table 4| Impact of quadrivalent HPV vaccine on incidence of subsequent HPV related disease among women who had a diagnosis of vulvar
or vaginal disease*
% reduction (95% CI) in
rate with vaccine
Placebo (n=475)Vaccine (n=229)
End point Rate‡
No of women with a
lesion†Rate‡
No of women with a
lesion†
HPV related disease irrespective of causal HPV type
35.2 (13.8 to 51.8)31.0163/42220.170/211Any disease:
46.3 (22.0 to 63.7)18.2110/4219.839/210Cervical intraepithelial neoplasia
grade I or worse
35.6 (−11.9 to 64.3)7.247/4134.719/209Genital warts
18.4 (−31.1 to 50.3)8.454/4136.928/209Vulvar or vaginal intraepithelial
neoplasia grade I or worse
40.8 (−14.6 to 71.3)5.135/4213.013/210Cervical intraepithelial neoplasia
grade II or worse
18.5 (−82.5 to 65.9)2.820/4212.310/210Cervical intraepithelial neoplasia
grade III or worse
23.5 (−63.3 to 66.4)3.423/4132.611/209Vulvar or vaginal intraepithelial
neoplasia grade II or worse
Disease related to vaccine HPV types (6, 11, 16, or 18)
64.4 (41.6 to 79.3)13.884/4224.920/211Any disease:
71.8 (39.5 to 88.5)6.644/4211.98/210Cervical intraepithelial neoplasia
grade I or worse
60.4 (19.1 to 82.3)5.939/4132.410/209Genital warts
54.5 (−16.5 to 85.0)3.121/4131.46/209Vulvar or vaginal intraepithelial
neoplasia grade I or worse
57.7 (−17.0 to 87.7)2.719/4211.15/210Cervical intraepithelial neoplasia
grade II or worse
25.8 (−131.8 to 79.8)1.511/4211.15/210Cervical intraepithelial neoplasia
grade III or worse
63.0 (−34.8 to 93.2)1.913/4130.73/209Vulvar or vaginal intraepithelial
neoplasia grade II or worse
HPV=human papillomavirus.
*Any HPV related disease detected ≥60 days after diagnosis of genital warts, vulvar intraepithelial neoplasia, or vaginal intraepithelial neoplasia.
†Number of women with at least one follow-up visit for the respective end point after surgery. A woman is counted only once for each end point (that is, once in
each row) but may have developed more than one end point (and so may appear in more than one row).
‡Cases per 100 person years at risk.
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Figures
Fig 1 Study design for assessing effect of quadrivalent HPV vaccine on incidence of subsequent HPV related disease
among women who had undergone surgery for cervical disease or who were diagnosed with vulvar or vaginal disease.
Subsequent disease was measured from 60 days after surgery or diagnosis
Fig 2 Participant flow through study
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Fig 3 Incidence of HPV related disease detected ≥60 days after cervical surgery or diagnosis of vulvar or vaginal disease
among women who did not receive quadrivalent HPV vaccine (that is, placebo recipients)
Fig 4 Time to detection of any HPV related disease (A) or vulvar or vaginal disease (B) after cervical surgery; and of any
HPV related disease (C) or any cervical disease (D) after diagnosis of vulvar or vaginal disease. Case counting began 60
days after surgery or diagnosis
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